Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis

25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis

(2012) Pilar Peris et al.   BONE

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis

(2012) T. Lin et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?

(2012) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients with cirrhosis and ascites have false values of bone density

(2011) N. Guañabens et al.   OSTEOPOROSIS INTERNATIONAL

Parenteral Bisphosphonates for Osteoporosis in Patients With Primary Biliary Cirrhosis

(2010) Sombat Treeprasertsuk et al.   AMERICAN JOURNAL OF THERAPEUTICS

Liver and bone

(2010) Núria Guañabens et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis

(2010) Núria Guañabens et al.   GASTROENTEROLOGY

184 MONTHLY IBANDRONATE VS. WEEKLY ALENDRONATE IN THE TREATMENT OF OSTEOPOROSIS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS: SIMILAR EFFICACY BUT DIFFERENT ADHERENCE

(2010) A. Parés et al.   JOURNAL OF HEPATOLOGY

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

(2008) R. G. G. Russell et al.   OSTEOPOROSIS INTERNATIONAL